pPACK-SPIKE Delta (B.1.617.2), SARS-CoV-2 "S" Pseudotype - Delta (B.1.617.2) Variant - Lentivector Packaging MixUser Manual
Safely explore increased transmissibility and other features of the spike protein from the CDC variant of concern SARS-CoV-2 Delta (B.1.617.2)
- Based on SBI’s popular and highly cited pPACKH1 Packaging System
- Uses codon-optimized SARS-CoV-2 “S” protein from variant Delta (B.1.617.2, originally found in India) in place of VSV-G envelope protein
- Spike protein mutations are T19R, G142D, ΔE156-157, R158G, L452R, T478K, D614G, P681R, D950N
- Ideal for vaccine and antiviral efficacy studies under BSL2 conditions
- Package any 3rd-generation lentivector reporter of your choice, including SBI’s popular LentiLabeler reporters
- Compare with our full range of pPACK-SPIKE S protein pseudotyped lentiviruses to better understand emerging variants
- Use with pPACK-BALD™, an envelope protein-free lentivector packaging system that is an ideal negative control
Potentially more transmissible than previous SARS-CoV-2 variants, the Delta variant (B.1.617.2) is classified as a variant of concern by the Centers for Disease Control (CDC) in the United States. This variant was initially observed in India and has since spread globally. With the pPACK-SPIKE™ Delta (B.1.617.2) Variant Spike Protein Lentivector Packaging Mix, you can safely characterize the SARS-CoV-2 S1 spike protein from lineage Delta (B.1.617.2), which contains the following mutations:
Designed to efficiently package most third-generation lentivectors, the pPACK-SPIKE Delta (B.1.617.2) Variant Spike Protein Lentivector Packaging Mix speeds and simplifies preparation of lentiviral particles pseudotyped with the SARS-CoV-2 T19R, G142D, ΔE156-157, R158G, L452R, T478K, D614G, P681R, D950N spike glycoprotein, making it an ideal reagent for vaccine and antiviral drug discovery projects.
Based on SBI’s highly cited pPACKH1 packaging system but with a truncated T19R, G142D, ΔE156-157, R158G, L452R, T478K, D614G, P681R, D950N Spike protein  replacing the standard VSV-G envelope protein, the pPACK-SPIKE Delta (B.1.617.2) Variant Spike Protein Packaging Mix consists of three plasmids that produce all of the structural and replication proteins needed to transcribe and package an RNA copy of an expression lentivector into recombinant, T19R, G142D, ΔE156-157, R158G, L452R, T478K, D614G, P681R, D950N “Spike” pseudotyped lentiviral particles. As a result, you can conduct a range of SARS-CoV-2 studies under BSL-2 conditions, including neutralization assays, studies of virus interactions with host surface proteins, and the development of vaccines and therapeutics.
For added convenience we offer pPACK-BALD™, an envelope protein-free lentivector packaging mix that can be used as a negative control for any pPACK-SPIKE study, or for creating lentivirus particles pseudotyped with the envelope protein of your choice.
In addition, ACE2-expressing stable cell lines are provided.
pPACK-SPIKE Delta (B.1.617.2) Variant Spike Protein Lentivector Packaging Mix is available as stand-alone packaging mixes with sufficient plasmids for 10 reactions (standard size) or 25 reactions (XL), as well as the pPACK-SPIKE Beta Combo Kit that includes PureFection™ Transfection Reagent and PEG-it Virus Precipitation Solution.
How It Works
pPACK-SPIKE is easy to use - simply co-transfect the pPACK-SPIKE Plasmids and your lentivector construct into 293TN producer cells or other lentiviral production cells, isolate pseudoviral particles with an optional concentration step, and conduct your studies.
Available pPACK-SPIKE S protein variants
|Catalog Number||Spike Variant||WHO label||Spike Protein Mutation|
|CVD19-500A-1-SBI||SARS-CoV-2 “S” Pseudotype||Original Wuhan-Hu-1 strain|
|CVD19-590A-1-SBI||B.1.1.7 (UK) Variant||Alpha||ΔH69/V70, ΔY144, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H|
|CVD19-580A-1-SBI||B.1.351 (S.A.) RBD Mutations||Beta||K417N, E484K, & N501Y|
|CVD19-600A-1-SBI||B.1.351 (S.A.) S1 Mutations (RBD+D614G)||Beta||K417N, E484K, N501Y, & D614G|
|CVD19-640A-1-SBI||B.1.351 (S.A.) complete spike mutations||Beta||ΔH69/V70, Q52R, E484K, D614G, Q677H, F888L|
|CVD19-610A-1-SBI||B.1.429 (CAL.20C) Variant||Epsilon||S13I, W152C, L452R, & D614G|
|CVD19-620A-1-SBI||B.1.525 Variant||Eta||ΔH69/V70, Q52R, E484K, D614G, Q677H, & F888L|
|CVD19-630A-1-SBI||P1 Variant||Gamma||L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I, V1176F|
|CVD19-650A-1-SBI||B.1.617.2 Variant||Delta||T19R, G142D, ΔE156-157, R158G, L452R, T478K, D614G, P681R, D950N|
- Ou X, et al. (2020) Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat. commun.